Evidence map›Paper›PMID 38686919›Full record

ArticleeLife2024

Digital wearable insole-based identification of knee arthropathies and gait signatures using machine learning.

Matthew F Wipperman, Allen Z Lin, Kaitlyn M Gayvert, Benjamin Lahner, Selin Somersan-Karakaya, Xuefang Wu, Joseph Im, Minji Lee, Bharatkumar Koyani, Ian Setliff and 16 more

Abstract read
In one paragraph

Article in eLife, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Personalizing the Management of Knee Osteoarthritis.SMART-MD journal of precision medicine · 2026
    Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Matthew F Wipperman *Precision Medicine, Regeneron Pharmaceuticals Inc, Tarrytown, United States.ORCID https://orcid.org/0000-0003-1436-3366
Allen Z Lin *Molecular Profiling & Data Science, Regeneron Pharmaceuticals Inc, Tarrytown, United States.ORCID https://orcid.org/0000-0001-5105-308X
Kaitlyn M Gayvert *Molecular Profiling & Data Science, Regeneron Pharmaceuticals Inc, Tarrytown, United States.ORCID https://orcid.org/0000-0001-9135-6501
Benjamin LahnerPrecision Medicine, Regeneron Pharmaceuticals Inc, Tarrytown, United States.
Selin Somersan-KarakayaEarly Clinical Development & Experimental Sciences, Regeneron Pharmaceuticals Inc, Tarrytown, United States.
Xuefang WuClinical Outcomes Assessment and Patient Innovation, Global Clinical Trial Services, Regeneron Pharmaceuticals Inc, Tarrytown, United States.
Joseph ImClinical Outcomes Assessment and Patient Innovation, Global Clinical Trial Services, Regeneron Pharmaceuticals Inc, Tarrytown, United States.
Minji LeeMolecular Profiling & Data Science, Regeneron Pharmaceuticals Inc, Tarrytown, United States.
Bharatkumar KoyaniClinical Outcomes Assessment and Patient Innovation, Global Clinical Trial Services, Regeneron Pharmaceuticals Inc, Tarrytown, United States.
Ian SetliffMolecular Profiling & Data Science, Regeneron Pharmaceuticals Inc, Tarrytown, United States.
Malika ThakurClinical Outcomes Assessment and Patient Innovation, Global Clinical Trial Services, Regeneron Pharmaceuticals Inc, Tarrytown, United States.
Daoyu DuanPrecision Medicine, Regeneron Pharmaceuticals Inc, Tarrytown, United States.
Aurora BreaznaBiostatistics and Data Management, Regeneron Pharmaceuticals Inc, Tarrytown, United States.
Fang WangPrecision Medicine, Regeneron Pharmaceuticals Inc, Tarrytown, United States.
Wei Keat LimMolecular Profiling & Data Science, Regeneron Pharmaceuticals Inc, Tarrytown, United States.ORCID https://orcid.org/0000-0002-6226-2570
Gabor HalaszMolecular Profiling & Data Science, Regeneron Pharmaceuticals Inc, Tarrytown, United States.
Jacek UrbanekBiostatistics and Data Management, Regeneron Pharmaceuticals Inc, Tarrytown, United States.
Yamini PatelGeneral Medicine, Regeneron Pharmaceuticals Inc, Tarrytown, United States.
Gurinder S AtwalMolecular Profiling & Data Science, Regeneron Pharmaceuticals Inc, Tarrytown, United States.
Jennifer D HamiltonPrecision Medicine, Regeneron Pharmaceuticals Inc, Tarrytown, United States.
Samuel StuartClinical Outcomes Assessment and Patient Innovation, Global Clinical Trial Services, Regeneron Pharmaceuticals Inc, Tarrytown, United States.
Oren LevyEarly Clinical Development & Experimental Sciences, Regeneron Pharmaceuticals Inc, Tarrytown, United States.
Andreja AvbersekEarly Clinical Development & Experimental Sciences, Regeneron Pharmaceuticals Inc, Tarrytown, United States.
Rinol AlajClinical Outcomes Assessment and Patient Innovation, Global Clinical Trial Services, Regeneron Pharmaceuticals Inc, Tarrytown, United States.
Sara C HamonPrecision Medicine, Regeneron Pharmaceuticals Inc, Tarrytown, United States.
Olivier HarariEarly Clinical Development & Experimental Sciences, Regeneron Pharmaceuticals Inc, Tarrytown, United States.ORCID https://orcid.org/0000-0001-8214-489X

Funding

Regeneron Pharmaceuticals N/A
6 · The paper itself

Abstract

Gait is impaired in musculoskeletal conditions, such as knee arthropathy. Gait analysis is used in clinical practice to inform diagnosis and monitor disease progression or intervention response. However, clinical gait analysis relies on subjective visual observation of walking as objective gait analysis has not been possible within clinical settings due to the expensive equipment, large-scale facilities, and highly trained staff required. Relatively low-cost wearable digital insoles may offer a solution to these challenges. In this work, we demonstrate how a digital insole measuring osteoarthritis-specific gait signatures yields similar results to the clinical gait-lab standard. To achieve this, we constructed a machine learning model, trained on force plate data collected in participants with knee arthropathy and controls. This model was highly predictive of force plate data from a validation set (area under the receiver operating characteristics curve [auROC] = 0.86; area under the precision-recall curve [auPR] = 0.90) and of a separate, independent digital insole dataset containing control and knee osteoarthritis subjects (auROC = 0.83; auPR = 0.86). After showing that digital insole-derived gait characteristics are comparable to traditional gait measurements, we next showed that a single stride of raw sensor time-series data could be accurately assigned to each subject, highlighting that individuals using digital insoles can be identified by their gait characteristics. This work provides a framework for a promising alternative to traditional clinical gait analysis methods, adds to the growing body of knowledge regarding wearable technology analytical pipelines, and supports clinical development of at-home gait assessments, with the potential to improve the ease, frequency, and depth of patient monitoring.

Indexed as

GaitMachine LearningOsteoarthritis, KneeWearable Electronic DevicesAgedFemaleGait AnalysisHumansMaleMiddle Agedclinical AI/MLdata analysisdigital biomarkersdigital health technologydigital medicinegaithumanmedicineneurosciencewearables

Identifiers

PMID38686919
PMCPMC11152572

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.